BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
MWN-AI** Summary
BioVie Inc. (NASDAQ: BIVI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological conditions, has announced that two abstracts will be presented at the 2026 American College of Psychiatrists (ACP) annual meeting, scheduled for February 18-22 in Bonita Springs, FL. The two studies feature bezisterim (NE3107), BioVie’s lead candidate, which is being investigated for its potential to treat Alzheimer’s Disease and Long COVID.
The first abstract, titled "Bezisterim-Associated Anti-inflammatory Epigenetic Modulation of Age Acceleration and Cognition in Alzheimer’s Disease,” discusses how bezisterim modulates key pathways involved in neuroinflammation, potentially leading to cognitive improvements in Alzheimer’s patients. The second abstract provides insights into the "Baseline Characteristics of Currently Enrolled Participants in Phase 2 Study of Bezisterim in Long COVID," focusing on the ongoing ADDRESS-LC trial. This study aims to evaluate whether bezisterim can help alleviate neurological symptoms such as brain fog and fatigue associated with Long COVID.
Bezisterim, an oral drug capable of crossing the blood-brain barrier, is designed to reduce inflammation and improve insulin sensitivity with minimal side effects. Previous studies in Parkinson’s disease have indicated its efficacy when combined with traditional treatments like levodopa, with positive results enhancing motor control and reducing side effects common to Parkinson’s therapies. The upcoming trials for both Alzheimer’s and Long COVID are crucial as they aim to address pressing unmet medical needs and may offer new treatment avenues for millions of patients.
BioVie is also advancing its therapy BIV201 for advanced liver disease, demonstrating its commitment to addressing complex medical conditions. For more details, visit BioVie’s website.
MWN-AI** Analysis
BioVie Inc. (NASDAQ: BIVI) stands at a pivotal junction in its trajectory, particularly following the acceptance of two abstracts for presentation at the 2026 American College of Psychiatrists annual meeting. The company's lead drug candidate, bezisterim (NE3107), shows promise in treating conditions such as Alzheimer's Disease and Long COVID. Given the growing prevalence of these conditions, BioVie’s innovative approach to neuroinflammation may be timely and relevant, potentially positioning the company as a key player in the biopharmaceutical landscape.
Investors should closely monitor developments surrounding the presentations of the abstracts. Positive data regarding bezisterim's anti-inflammatory properties and its impact on cognitive function could catalyze significant interest, driving share prices upwards. Furthermore, the ongoing Phase 2 studies in Parkinson’s and Long COVID may bolster investor confidence as they progress towards respective topline data releases expected in mid-2026.
BioVie’s focus on targeting neuroinflammation and insulin resistance in diverse diseases suggests a robust pipeline. The company is also pursuing advancements in advanced liver disease with BIV201, diversifying its risk exposure in the pharmaceutical space. Given the FDA Orphan and Fast Track designations for BIV201, this product could provide an additional revenue stream and present a compelling investment case.
However, investors should also be mindful of the inherent risks associated with clinical-stage companies. The outcomes of ongoing trials are unpredictable, and regulatory hurdles could impose challenges. It is crucial to assess these risk factors alongside the potential for reward. In conclusion, BioVie warrants a buy recommendation, contingent upon favorable trial results and the continued de-risking of its pipeline through strategic presentations and publications, which may have profound implications for its market valuation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CARSON CITY, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of two abstracts from studies on its lead candidate bezisterim (NE3107), in the treatment of Alzheimer’s Disease and Long COVID at the 2026 American College of Psychiatrists (ACP) annual meeting, to be held February 18-22, in Bonita Springs, FL.
The two abstracts have been accepted for presentation as posters during a session to be held on February 18, 2026. Details of the abstracts are as follows:
Abstract Title: Bezisterim-Associated Anti-inflammatory Epigenetic Modulation of Age Acceleration and Cognition in Alzheimer’s Disease
Authors: Joseph M. Palumbo1; Christopher L. Reading1; Jiayan Yan1, Clarence Ahlem1; Penelope Markham1; Stephen O’Quinn1; Varun B. Dwaraka2
Abstract Title: Baseline Characteristics of Currently Enrolled Participants in Phase 2 Study of Bezisterim (NE3107) in Long COVID (ADDRESS-LC)
Authors: Joseph M. Palumbo1*; Penelope Markham1; Michael Peluso3; Igor J. Koralnik4; Sherry Hsiang-Yi Chou4; Lisa McCorkell5; Chantal Petit6; Stephen O’Quinn7; Chris Reading1; Clarence Ahlem1; Jiayan Yan1
Affilations: 1BioVie Inc., 2TruDiagnostic, Inc., 3University of California, San Francisco; 4Feinberg School of Medicine, Northwestern University; 5Patient-Led Research Collaborative, Oakland, California; 6Biotechnant Solutions LLC; 7Perissos Inc.
About Bezisterim
Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NF?B, TNF-?), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease, Long COVID, and Alzheimer’s disease.
In Parkinson’s disease, BioVie has already completed a Phase 2 study that showed patients with moderate- to severe Parkinson’s taking bezisterim with levodopa had better motor control and fewer morning symptoms compared to those taking levodopa alone. Few drug-related side effects were observed. The current SUNRISE-PD just completed enrolling 60 patients to evaluate whether bezisterim alone can help improve motor and non-motor symptoms for Parkinson’s patients who have not been treated with carbidopa/levodopa. Topline results are expected in mid?2026.
For Long COVID, the ADDRESS-LC trial is enrolling about 200 patient to evaluate if bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms associated with Long Covid, which are believed to be triggered by persistent circulation of spike protein fragments that trigger inflammation via NF?B activation (which bezisterim has been shown to modulate). Topline data is expected mid-2026.
In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with Alzheimer’s.
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.
In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.
| For Investor Relations Inquiries: | For Media Inquiries: |
| Contact: Chuck Padala Managing Director, LifeSci Advisors, LLC chuck@lifesciadvisors.com | Contact: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com |
FAQ**
What are the key findings presented in the abstracts regarding bezisterim's effectiveness in treating Alzheimer’s Disease and Long COVID as stated by BioVie Inc. BIVI?
How does bezisterim modulate neuroinflammation pathways, and what implications does this have for future treatments according to BioVie Inc. BIVI's research?
What are the expected timelines for the topline results of the SUNRISE-PD and ADDRESS-LC trials as noted by BioVie Inc. BIVI?
How does BioVie Inc. BIVI plan to advance its research on bezisterim in light of the promising early results in cognition and biomarkers for Alzheimer’s Disease?
**MWN-AI FAQ is based on asking OpenAI questions about BioVie Inc. (NASDAQ: BIVI).
NASDAQ: BIVI
BIVI Trading
-3.62% G/L:
$1.33 Last:
9,628 Volume:
$1.31 Open:
